Mumbai-based healthtech startup Neodocs has secured $2 million in a seed funding round, with Omidyar Network India, Y Combinator, and 9 Unicorns spearheading the investment, among other notable backers. Specializing in the development of smartphone-based health test kits, the startup enables users to conduct a variety of health tests conveniently from their homes, using only their smartphones and a test card.
Neodocs is poised to strengthen its product portfolio, with a particular emphasis on its kidney care and urinary tract infections (UTI) kits. Additionally, the company has unveiled a new product: an instant finger-prick blood test that provides rapid results directly on the user’s smartphone.
The raised capital will help the startup expand its presence into international markets, including Europe, Australia, the Middle East, the Philippines, and the United States, to address the global need for accessible and easy-to-use diagnostic solutions, as per the company’s statement.
Neodocs boasts partnerships with prominent pharmaceutical companies such as Cipla, Sun Pharma, and AstraZeneca, which have played a pivotal role in standardizing test results across various conditions, thereby enhancing reliability and accessibility.
In addition, Neodocs is collaborating closely with the governments of Maharashtra and Rajasthan to introduce digital testing in remote areas of India. Co-founded by Nikunj Malpani, Anurag Meena, and Pratik Lodha, Neodocs envisions a future where healthcare takes a proactive rather than reactive approach. By empowering doctors to swiftly screen and diagnose patients, the startup facilitates prompt treatment, aiming to revolutionize the healthcare landscape by shifting towards preventive measures.
Neodocs reports having sold over 200,000 test cards and garnered support from over 4,000 doctors nationwide. The startup is now setting its sights on selling over 10 million test kits by the coming year, aiming to make significant strides in advancing accessible and proactive healthcare.
